PSP Research LLC Acquires Shares of 10,758 Supernus Pharmaceuticals, Inc. $SUPN

PSP Research LLC acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,758 shares of the specialty pharmaceutical company’s stock, valued at approximately $535,000.

A number of other hedge funds also recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 268 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Supernus Pharmaceuticals by 1.7% during the 3rd quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after buying an additional 277 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Supernus Pharmaceuticals by 2.0% during the 3rd quarter. Amalgamated Bank now owns 16,030 shares of the specialty pharmaceutical company’s stock worth $766,000 after buying an additional 313 shares during the last quarter. Finally, Covestor Ltd increased its holdings in shares of Supernus Pharmaceuticals by 16.2% during the 4th quarter. Covestor Ltd now owns 2,683 shares of the specialty pharmaceutical company’s stock worth $133,000 after buying an additional 374 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SUPN. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Finally, Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $62.17.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frederick M. Hudson sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $50.61, for a total transaction of $271,725.09. Following the sale, the director directly owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. This trade represents a 8.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 120,881 shares of company stock worth $6,139,356. 8.80% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Stock Down 1.5%

NASDAQ:SUPN opened at $47.62 on Wednesday. The company has a fifty day simple moving average of $50.29 and a two-hundred day simple moving average of $49.79. The company has a market cap of $2.76 billion, a price-to-earnings ratio of -93.37, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57. Supernus Pharmaceuticals, Inc. has a 52 week low of $30.83 and a 52 week high of $59.68.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.